OBGYN.net Menopause & Perimenopause Section: The GynEndo Newsletter Archive

Article

The Editorial: Timing is Everything…  - A. R. Genazzani, MD., Ph.D., FRCOG, President, The International Society of Gynecological Endocrinology (ISGE)

Reprinted with permission of Andrea R. Genazzani, MD
& GynoEndo News   September 2006 Issue

The Editorial: Timing is Everything…  - A. R. Genazzani, MD., Ph.D., FRCOG, President, The International Society of Gynecological Endocrinology (ISGE)

The Interview: Three Questions to the Editorials Author

October 2006 Issue

The Editorial: Why Are Estrogens Rarely Used for the Treatment of Depression in Women? - J. Studd, DSc, MD, FRCOG, Chelsea & Westminster Hospital, London

The Interview: Three Questions to the Editorials Author

November 2006 Issue

The Editorial: LH Neither Too High Nor Too Low - Pedro N. Barri, Juan Balasch

The Interview: Three Questions to the Editorials Author

January 2007 Issue

The Editorial: Progesterone and Progesterone Receptor Modulator in Uterine Leiomyoma Growth - Takeshi Maruo

The Interview: Three Questions to the Editorials Author

© International Society of Gynecological Endocrinology

 

Related Videos
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
How to manage bone health in midlife women | Image Credit: - endocrine.org
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting | Image Credit: nursebarb.com
How fezolinetant changes management of hot flashes | Image Credit: medschool.cuanschutz.edu.
Fezolinetant effective against vasomotor symptoms | Image Credit: med.unc.edu
Gloria Richard-Davis MD, MBA, NCMP, FACOG
Related Content
Hormone therapy safety: Study finds potential benefits for senior women | Image Credit: © Graphicroyalty - © Graphicroyalty - stock.adobe.com.

Hormone therapy safety: Study finds potential benefits for senior women

April 24th 2024
Article

A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.

Read More

S3 E19: Alyssa Dweck, MD, on menopause products, her podcast, and more

S3 E19: Alyssa Dweck, MD, on menopause products, her podcast, and more

November 4th 2021
Podcast

In this episode, Michael Krychman, MD, sat down with Alyssa Dweck, MD, gynecologist, and Bonafide medical advisor to catch up at this year's North American Menopause Society (NAMS) Annual Meeting.

Listen

Maximizing your menopause health care visit | Image Credit: © Monkey Business - © Monkey Business - stock.adobe.com.

Maximizing your menopause health care visit

April 8th 2024
Article

Learn how to prepare for your menopause healthcare visit effectively and make the most out of your time with health care professionals, as advised by experts selected by The Menopause Society.

Read More

Actress Kim Cattrall on Menopause

Actress Kim Cattrall on Menopause

October 1st 2014
Podcast

Actress Kim Cattrall discusses her menopause journey and partnership with Tune In To Menopause, an awareness campaign designed to empower women.

Listen

Contemporary OB/GYN week in review: vasomotor symptoms, OTC contraceptive, and more | Image Credit: © Aleksey 159 - © Aleksey 159 - stock.adobe.com.

Contemporary OB/GYN week in review: vasomotor symptoms, OTC contraceptive, and more

March 25th 2024
Article

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Read More

Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial | Image Credit: © highwaystarz - © highwaystarz - stock.adobe.com.

Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial

March 19th 2024
Article

Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.

Read More

© 2024 MJH Life Sciences

All rights reserved.